Biblio Discovery — Demo Discovery Service

6 hasil untuk "Alex Shepherd"

Menampilkan 1–6 · 0,71 detik · RSS

  1. Artikel Jurnal

    A Flow Cytometry–Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells

    Alex Shepherd; Bigitha Bennychen; Ahmed Zafer dkk.

    Bio-Protocol, Vol. 14 No. 12 · 2024 · Inggris · DOAJ Scopus

    Chimeric antigen receptors (CARs) are synthetic fusion proteins that can reprogram immune cells to target specific antigens. CAR-expressing T cells have emerged as an effective treatment method for hematological cancers; despite this success, the mechanisms and structural properties that govern CAR…

  2. Artikel Jurnal Teks lengkap

    A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies

    Alex Shepherd; Bigitha Bennychen; Anne Marcil dkk.

    PLOS ONE, Vol. 18 No. 6 · 2023 · Inggris · PLOS Scopus

    Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple antibody-binding domains to induce active contact between T-cells and antigen expressing cells in the body. Blinatumomab, a CD19-CD3 BiTE is now a widely used therapy for relapsed B-cell malignancies…

    Juga tersedia di: DOAJ, DOAJ

  3. Artikel Jurnal

    Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation

    Scott McComb; Tina Nguyen; Alex Shepherd dkk.

    Frontiers in Immunology, Vol. 13 · 2022 · Inggris · DOAJ Scopus

    Epidermal growth factor family receptor (EGFR) is commonly overexpressed in many solid tumors and an attractive target for chimeric antigen receptor (CAR)-T therapy, but as EGFR is also expressed at lower levels in healthy tissues a therapeutic strategy must balance antigenic responsiveness against…

  4. Artikel Jurnal

    Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

    Scott McComb; Mehdi Arbabi-Ghahroudi; Kevin A. Hay dkk.

    Molecular Therapy: Oncology, Vol. 32 No. 1 · 2024 · Inggris · DOAJ Scopus

    Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains common. Camelid single-domain antibodies (sdAbs or nanobodies) are smaller, simpler, and easier to…